Abel De La Rosa, PhD
Chief Scientific Officer
Drug Innovation Ventures at Emory &
Emory Institute for Drug Development, Emory University

Dr. De La Rosa is the Chief Scientific Officer of the Drug Innovation Ventures at Emory and the Emory Institute for Drug Development. He is responsible for the scientific strategy and management of R&D activities of both organizations. From 2002 until its acquisition by Gilead Sciences (Nasdaq: GILD) for $11 billion in 2012, Dr. De La Rosa was Senior Vice President of Business Development & Scientific Affairs with Pharmasset. He was responsible for licensing, strategic transactions, and alliance management of collaborations and partnerships with pharmaceutical companies and universities. He provided business and scientific leadership to drug development programs for the treatment of HIV, Hepatitis B and Hepatitis C, including Sofosbuvir (Sovaldi). Prior to Pharmasset, Dr. De La Rosa held both scientific and business positions at Visible Genetics, where he was responsible for the development and improvement of sequencing-based diagnostic tests for HIV, Hepatitis B and Hepatitis C. Dr. De La Rosa also held scientific positions at Innogenetics, Boston Biomedica, and Digene, developing molecular diagnostic tests for infectious diseases. He is an inventor and author on several U.S. patents and publications relating to molecular diagnostic methods, techniques and therapeutics for infectious diseases and cancer, and has served on Scientific Advisory Boards and company Boards.

Dr. De La Rosa earned a Fogarty Fellowship and an Intramural Research Training Award Fellowship from the National Institutes of Health, where he completed post-doctoral training in the Laboratory of Biochemistry and the Laboratory of Pathology of the National Cancer Institute. He holds a Bachelors Degree in Microbiology from the University of California, San Diego, and a Ph.D. in Microbiology from Miami University.